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An update on the referral pattern of patients with end-stage EPIDEMIOLOGY OF LATE REFERRAL
renal disease. This article first describes the epidemiology and FOR ESRD
reasons of late referal to the nephrologist of patients suffering
Table 1 is a summary of some selected data. It shouldfrom end-stage renal disease (ESRD). Depending on the defi-
nition, between 25 and 50% of worldwide ESRD patients are be noted that the definition used in several of the articles
referred very late. Second, the relation of late referral to the is not uniform, explaining some of the differences in
quality of pre-ESRD care, its impact on the selection of dialysis referral patterns in the different countries.
modality, on the time of start of dialysis and on the use of an
It is also remarkable that there has been no improve-adequate vascular access, are discussed. Finally, the economic
ment over the years in these figures, despite previousaspects of late referral are described and ways to improve the
referral pattern are proposed. attention to the problem of late referral (LR) with all
its associated higher morbidity, mortality, and negative
economic side effects [4–8].
Although more recent articles [9–13] have found thatThe incidence of end-stage renal failure (ESRF) is
rising exponentially both in Europe and the United both early and late patient survival were lower in late-
States [1–3]. One reason for this phenomenon is an in- referred patients, this has not been universally found
creasing number of patients starting renal replacement [14–16]. However, almost all studies describe a higher
therapy (RRT), but improving survival of patients on co-morbidity in the late-referred patients, necessitating
RRT may also contribute. The age threshold of elderly longer duration of the initial hospitalization.
patients considered suitable for dialysis has also risen
continuously. In the United States, over 30% of those
REASONS FOR LATE REFERRRALon the RRT program are aged older than 65, while in
One explanation may be the insidious evolution ofsome European countries, like Germany and Greece,
chronic renal failure in the majority of the patients. Inthis percentage is over 50% and 40%, respectively [3].
some patients, renal insufficiency only becomes obviousAll over the world, where at least some data are avail-
with the appearance of frank uremic symptoms, leadingable, between 20% and over 50% of those patients taken
to consultation with a physician. This type of problemonto dialysis require RRT within days or weeks. The
can only been avoided by regular screening of renalmost important reason for this late start of RRT is a
function in otherwise asymptomatic patients, which isdelayed referral of the patient to the nephrology units.
economically unrealistic. However, some categories ofThis article will attempt to describe the most recent
the population may be considered to be at high riskepidemiology and possible reasons for this phenomenon,
for developing renal insufficiency, such as patients agedas well as the associated negative medical and socio-
50–75 years who have either hypertension or diabetes.economic consequences, and try to explore ways to im-
A recent retrospective study has explored the possibilit-prove the referral pattern over the coming years.
ies of screening such patients [17]. Primary care case
notes and computer records in 12 general practices from
1 Present address: University Hospital, 185, De Pintelaan, 9000 Ghent, inner and greater London were audited to see whether
Belgium. patients had their blood pressure measured and urine
tested for protein within 12 months, and plasma creati-Key words: patient referral, pre-ESRD care, vascular access, dialysis
initiation. nine measured within 24 months. A total of 16,855 pa-
tients were aged 50–75 years. From this age group, 2693 2002 by the International Society of Nephrology
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Table 1. Recent publications on late referral in several countries
Fraction of
Reference Country Time period Definition of LR population %
[30] USA Oct 92–Dec 97 4 months 20
[61] Oct 95–June 96 1 month 25
1–4 months 15
[49] 1990–1994 no nephrol care 57
[16] Jan 90–April 97 1 month
[64] European survey Jan 93–Dec 95 1 month 35
[65] Jan 96–Dec 97 1 month 35
[8] France Jan 89–Dec 91 1 month 29
[15] Jan 89–Dec 96 4 months 31
[11] Scotland Oct 97–Sept 98 Unplanned 24.2
Unrecovered ARF 10.7
Acute-on-chronic 11.8
[55] The Netherlands Jan 97–May 99 Below DOQI guidelines 37
[9] Spain 1996–1997 6 months 23
[35] Brasil 1 month 57
(15.5%) patients were identified as being either hyper- period, 72% of this group had abnormal SCr, while 18%
had normal SCr with abnormal Cockroft-Gault values;tensive or diabetic, or both. Of the 2561 records audited,
1359 (53.1%) contained a plasma creatinine measured 10% had normal SCr with normal Cockroft-Gault values.
Thus this study documents the substantial prevalencewithin 24 months, and 11% (150) of these had a value
of 125 mol/L. This equates a prevalence of renal of significantly abnormal renal function among patients
identified by laboratories as having normal-range SCr.insufficiency with 110,000 patients per million in this
group, but only 42 patients (28%) had been referred to Although the inclusion of calculated estimates of GFR
in routine laboratory reporting may help to facilitatea nephrologist. Of records audited, 73% contained a
blood pressure measurement and 29% contained a test the early identification of asymptomatic patients with
incipient renal impairment, one should realize the prob-for proteinuria within 12 months. It is clear that a com-
plete referral of all appropriate patients would over- lems associated with the use of serum creatinine as mea-
surement of renal function. These problems are wellwhelm the available renal services in that area. However,
this large population could be managed in the commu- known to the nephrologist but not to other practitioners,
including general practitioners and non-nephrology spe-nity, but clinical care pathways need to be developed to
screen, investigate, and manage these patients at risk. cialists. The serum creatinine concentration increases as
the GFR declines; however, creatinine levels are affectedRealistically, such protocols could be supervised by prac-
tice and community nurses. by many factors beyond the GFR. In addition to the
confounding effect of the tubular secretion of creatinineA similar study was recently performed in Canada [18]
and included 2781 outpatients referred by community when renal function deteriorates, creatinine production
also varies significantly depending on both muscle massphysicians to an urban laboratory network for serum
creatinine (SCr) measurement. Glomerular filtration rates and dietary factors. These differences lead to significant,
GFR-independent, inter-individual variations in serum(GFR) were estimated using the Cockroft-Gault for-
mula, in view of the well-known fact that many patients creatinine levels. As a result, for individuals with low
baseline values, it has been estimated that serum creati-can have significantly decreased GFR with normal range
SCr values, making the recognition of renal dysfunction nine may increase by up to 13 standard deviations be-
yond the individual’s personal reference range beforemore difficult. The study patients were grouped ac-
cording to the concordance of SCr level abnormalities exceeding the upper limit of normal for the population
[19–21]. This highlights one of the major limitations of(abnormal 130 mol/L) with significantly abnormal
clearance values (abnormal50 mL/min). The Cockroft- serum creatinine in clinical practice. Thus, although re-
peated determinations are quite useful for trackingGault value of 50 mL/min was chosen to reflect sub-
stantial renal impairment in all age groups. Of the 2781 changes in GFR with time, a single serum creatinine
value is a relatively insensitive screening test for theoutpatients referred, 2543 (91.4%) had normal SCr levels.
Of these patients, 387/2543 (15.2%) had a calculated presence of mild to moderate decrements in filtration
function.GFR 50 mL/min, representing substantially impaired
renal function. Analysis of historical available laboratory As pointed out by Jungers [22], most of the measures
aimed at preventing or slowing renal insufficiency coulddata for patients with abnormal SCr and abnormal Cock-
roft-Gault values showed that 2 years prior to the study and should be implemented primarily upstream of the
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nephrologist, i.e., by general practitioners, internists, dia- zations were more likely to be referred late than patients
covered by Medicare.betologists, cardiologists, urologists, geriatricians, and
A recent US study [31] found by multivariate analysis,more generally by all health care providers. Early thera-
that women, Hispanics, and Asians compared with Cau-peutic intervention is especially desirable in high-risk
casians, uninsured patients compared with those pri-groups, namely diabetic and hypertensive patients, cer-
vately insurance, and employed patients were moretain ethnic minorities, or patients with systemic disease.
likely to start dialysis late. Certain nonclinical patientOne may expect that targeted intervention in well-
characteristics, notably female gender, race, and lack ofdefined populations particularly at risk of developing
insurance, are thus related to an increased likelihoodrenal disease and progressive renal insufficiency, such
of late initiation of dialysis. These factors may reflectas diabetic and/or hypertensive patients, will result in
reduced access to care.significant savings in terms of health for patients and
It is also possible that some LR patients are in factcosts to the community. Evidence has been provided
hidden nonreferrals, admitted in emergency often be-that search for microalbuminuria allows the detection
cause of pressure by the family. Kahn et al [32] in theof the initial step of renal involvement. At this stage,
United Kingdom and Mendelssohn et al [33] in Canadatherapeutic intervention by means of stringent blood
found that a substantial number of ESRD patients waspressure control, electively using angiotensin II neu-
not referred, the number increasing with age and co-tralizing agents, stops or retards evolution to macroalbu-
morbid conditions. This suggests that probably manyminuria and progressive renal failure. Even in patients
physicians decide for themselves whether RRT shouldwith established renal insufficiency, treatment with an-
or should not be used in a patient with certain co-morbidgiotensin-converting enzyme inhibitors (ACEIs) or an-
conditions without previously asking advice of a nephrol-giotensin receptor blockers [23–27] has been shown to
ogist.slow progression significantly in diabetics and non-dia-
It was found in Italy that the trend for LR was higherbetics with overt nephropathy, and the same is true for
in elderly patients. Therefore, it is difficult to foreseepatients with essential hypertension. Guidelines for pre-
the possible expansion of the dialytic pool in elderlyvention and optimal treatment of diabetic and/or hyper-
patients. Some of these frail or even seriously ill oldtensive nephropathy already exist and could easily be
patients may still appear in a dialysis unit where RRTimplemented by every informed physician.
is started in an attempt to improve their general condi-Another reason for the LR may be that some patients
tion. In some of these patients, RRT is indeed futile,may have consulted a non-nephrologist but have been
explaining the relatively high number of deaths fromreferred to a nephrologist too late; this can occur for a
withdrawal of dialysis in this category [6].variety of reasons. For example, the treating physician
Finally, some patients suffering from acute renal fail-may not be aware of the severity of the disease or of
ure do not recover and remain dialysis-dependent.the importance of adequate pre-end-stage renal disease
(ESRD) care. There may be inadequate communication
between the non-nephrologist and the renal physician; RELATION OF LR TO QUALITY OF
and in private institutions, there may be fear of loss of PRE-ESRD CARE
the patient, or reluctance to alarm the patient and his Theoretically, timely referral of patients with chronic
family. renal failure (CRF) to a nephrologist is likely to result
In some European countries, it has been suggested in an improved clinical condition and better preparation
that medical plethora might play an important role in for initiation of dialysis. Indeed, data from Europe [6,
the problem of LR [28]. 7, 9, 32, 34] and South America [35] have shown that
In a study conducted some years ago in several Flemish delayed referral is associated with a higher prevalence
centers in Belgium, it appeared that the largest number of uremic complications at the initiation of dialysis, with
of lately referred patients were last seen by cardiologists, increased hospitalizations and higher cost of care.
endocrinologists, and general internists, and to a lesser A study in the United States by Arora et al [30],
extent by general physicians [29]. Some of the patients found that 22% of the patients were LRs. There were
were followed by these specialists for preexisting moder- no differences in age, gender, race, and cause of ESRD
ate chronic renal failure and had a unexpectedly rapid between early referral (ER) and LR patients. However,
deterioration of renal function as a result of iatrogenic compared with ER, LR patients were more likely to
diagnostic or therapeutic procedures. have hypoalbuminemia (56% vs. 80%), hematocrit28%
Socio-economic reasons may be another explanation (33% vs. 55%), and predicted GFR 5 mL/min per 1.73
of LR. In a study by Arora et al [30], there were signifi- m2 (17% vs. 40%) at the start of dialysis, and less likely
cant differences in insurance coverage between the early to have received erythropoietin (40% vs. 17%) or have
a functioning permanent vascular access for the firstand LRs. Patients covered by health maintenance organi-
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hemodialysis (40% vs. 4%). However, pre-ESRD care of renal anemia indicated that only a small proportion
of patients (11%) began treatment with erythropoietinamong patients treated by a nephrologist for more than
4 months before initiation of renal replacement therapy before dialysis; that patients had low levels of hemoglo-
bin at the start of erythropoietin (9 g/dL), and thatwas also less than ideal. Even among ER, 56% had hypo-
albuminemia, 33% had a hematocrit 28%, only 40% low target levels were achieved after treatment. At least
based on this and the above-mentioned surveys, pre-had received predialysis erythropoietin, only 40% had
a functioning permanent vascular access for the first dial- ESRD care everywhere in the world is far from adequate
[39].ysis, and 17% started dialysis at a predicted GFR 5
mL/min per 1.73 m2. It is possible that the 4-month cutoff
that was used in this and other studies to define ER may
IMPACT OF LATE REFERRAL ON THEbe too liberal. Optimal pre-ESRD care would probably
SELECTION OF DIALYSIS MODALITYrequire referral to the nephrologist at an even earlier
ER has also been shown to empower the patient intime point in the course of progressive renal disease.
making therapeutic decisions based on pertinent infor-The National Institutes of Health (NIH) Consensus
mation and to affect the selection of specific dialyticConference of 1993 recommends that patients with CRF
modalities. Many reports have indicated that ER to abe referred to a renal team when the serum creatinine
nephrologist, combined with a responsible, well-bal-has increased to 1.5 mg/dL in women and 2.0 mg/dL in
anced presentation of all therapeutic options, is associ-men [36]. The median interval between the first encoun-
ated with a higher selection of peritoneal dialysis as ini-ter with the nephrologist and start of dialysis was 25
tial therapy [9, 10, 16, 40–44]. More significantly, amongmo among patients in the ER group. Consequently, an
patients referred to a nephrologist with no specific medi-alternative interpretation of these data could be that pre-
cal indications for peritoneal or hemodialysis, 50% ofESRD care of patients treated by nephrologists, too,
them selected peritoneal dialysis after an impartial intro-is less than ideal. The patient-, physician-, and system-
duction to both therapies [45]. ER provides the time forrelated factors behind this observation are currently un-
education before frank uremia ensues, allows the patientclear. It is concluded that also in the United States, LR
to participate in choosing the modality of therapy thatto the nephrologist is associated with poor pre-ESRD
best suits his or her individual lifestyle, and promotescare, but that ER not always guarantees optimal pre-
self therapy, all of which should have a significant impactESRD care. This is further illustrated by the study of
on quality of life and cost of treatment.Nissenson et al [37]. Among the 200,000 patients who
In LRs, sometimes arriving in an emergency situation,were enrolled in a health maintenance organization be-
the reasons to start RRT are often a pulmonary edematween 1994 and 1997, a cohort of 1,658 patients who
exhibited at least two gender-specific, elevated creatinine or other serious uremic symptoms. In such cases, an
concentrations, separated by at least 90 days, were identi- urgent hemodialysis session results in a prompt correc-
fied. The proportions of patients with creatinine values tion of clinical status. Moreover, motivating a patient to
of 2.0, 2.0–2.9, 3.0–3.9, and 4.0 mg/dL were 73%, start with peritoneal dialysis takes time and persuasive
17%, 3%, and 7%, respectively. The majority of patients talent from the dialysis team and confidence and compre-
were treated by a primary care physician until the creati- hension from the patient, which are often absent in the
nine values reached 3.0 mg/dL, at which time a nephrolo- LR patients. The impact of intensive education and infor-
gist was consulted. Care tended to be transferred to the mation on modality choice has previously been demon-
nephrologist when the creatinine reached 4.0 mg/dL. strated [44, 46].
Only 7.4% of patients received erythropoietin, but its A Canadian study has assessed that even in ER pa-
use increased as creatinine increased. Erythropoietin was tients, the cost/benefit of a pre-ESRD treatment-educa-
unlikely to be prescribed unless the patient had visited a tion program is in favor of such a multidisciplinary ap-
nephrologist. Fewer than 50% of all patients with chronic proach because of the significantly fewer urgent dialysis
kidney disease and fewer than 20% of patients with creat- starts, more outpatient training, and fewer hospital days
inine values of4.0 mg/dL received an ACEI. Nephrolo- in the first month of dialysis in the “educated” patients
gists were not more likely to prescribe these drugs than [47].
were primary care physicians. Diabetic patients were
more likely to receive angiotensin-converting enzyme
REFERRAL PATTERN AND MOMENT OFinhibitors than were nondiabetic patients, but use of
START OF DIALYSISthese drugs was quite low even among diabetic patients
There are no uniform objective criteria for the initia-with nephropathy.
tion of long-term dialysis therapy. Nephrologists initiateAlso in Europe, a recent survey revealed serious short-
dialysis treatment in most cases on the basis of the ob-comings in the management of renal anemia of pre-
ESRD patients [38]. The ESAM trial on management served evolution of uremic symptoms and laboratory
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investigations, such as plasma creatinine concentration incident patients in 1998 were 8.4 mL/min in Europe and
11.1 mL/min in the United States; in 1999 the valuesand creatinine clearance (CCr) [48]. However, the evolu-
tion of uremic symptoms varies from patient to patient were 8.6 mL/min and 10.8 mL/min, respectively [57]. It
thus seems that both in Europe and the United States[49], so there is substantial variation in timing of dialysis
initiation [50–52]. The study by Obrador et al [52] re- there is a tendency to start dialysis at higher GFR com-
pared with the past.vealed that there is wide variation in renal function at
the initiation of dialysis in the United States. ESRD It is important to note that in many European centers,
the residual renal function is, at least in most of the LRs,population, and a substantial fraction of patients (23%),
start dialysis at levels of predicted GFR below 5 mL/min. not the direct cause for initiation of dialysis. The decision
to initiate dialysis therapy is often based on clinical andIn an attempt to improve the quality and outcome
of dialysis care, the US National Kidney Foundation biochemical parameters, which should be frequently
evaluated in the pre-ESRD time frame. The frequencyDialysis Outcomes Quality Initiative was established
[53]. And, according these guidelines, dialysis should be of medical visits should be driven by clinical criteria,
including control of hypertension, compliance to medica-started when renal Kt/Vurea falls below 2.0/week. This
value equals a CCr of about 14 mL/min. A lower Kt/Vurea tions, control of hyperphosphatemia and PTH levels,
treatment of anemia, control of acid-base, and otherwould be acceptable only when the protein equivalent
of total nitrogen appearance normalized to body weight clinical considerations.
Moreover, it is not exceptional that urgent dialysis be(nPNA) falls below 0.8 g/kg per day. It would intuitively
be expected that LR patients, compared with ERs, would performed, mostly for pulmonary edema, sometimes at
clearances well above 10–12 mL/min. It appears how-start RRT at lower residual GFR; this was the case in
some [9, 30, 44] but not all studies. Various US studies ever, that, probably because of induced ultrafiltration,
the residual renal function rapidly falls to very low levels,showed a mean estimated GFR at onset of dialysis be-
tween 7.1 and 7.4 mL/min, [52, 54] and a European necessitating the continuation of dialysis.
multicenter study described a mean CCr of 7.4 mL/min
at the start of dialysis [10]. In a UK study, Kt/Vurea was IMPACT OF LR ON USE OF
1.05 (SD 0.4) per week at the initiation of dialysis [51].
VASCULAR ACCESSA recently published prospective cohort study in the
Previous cross-sectional studies have reported the as-Netherlands [55] found that better residual renal func-
sociation between ER to a nephrologist and greater AV-tion at the start of dialysis was associated with better
access use at the initiation of chronic hemodialysis ther-survival, but only a small beneficial effect of the DOQI
apy [29, 30, 58–60]. Woods et al [59] reported that 37%guideline for the optimum time to initiate dialysis was
of a sample of patients starting hemodialysis therapy infound with an observed gain in survival time of only 2.5
1996 used an AV access at their first dialysis session,months in the first 3 years after the start of dialysis. The
with 79% greater odds of using an AV access amongmean Kt/Vurea at start of dialysis was 1.3 (SD 0.6) per
patients referred to a nephrologist 4 or more months inweek. The authors concluded that an earlier start of
advance of the initiation of therapy. In the same popula-chronic dialysis in patients with ESRD than currently
tion, Stehman-Breen et al [58] found that patients toldapplied in the Netherlands (and probably in other indus-
they had renal disease more than 1 year before the starttrialized countries) is not warranted. A previous analysis
of hemodialysis therapy were nearly three times more[56], based on the same Netherlands Co-operative Study
likely to have an AV access in use at the start of hemodi-on the Adequacy of Dialysis (NECOSAD) database,
alysis therapy than those told 1–4 weeks before the starthad shown that, despite the low residual renal function
of hemodialysis therapy. Arora et al [30] found that 48%at start of dialysis in the Dutch patients, the large major-
of 86 patients referred to a tertiary-care center at least 4ity of them showed a good nutritional status, probably
months before the start of chronic hemodialysis therapyexplaining the lack of clear impact of late initiation of
used an AV access for their first dialysis session com-RRT in these patients.
pared with 4% of 28 patients referred later. These resultsIt should be mentioned that it is very difficult to ex-
were further extended in a recent analysis [61]. Patientsclude an important so-called lead-time bias in many of
who reported being seen by a nephrologist at least 1these studies. It is clear, however, that all the values of
month before starting hemodialysis therapy (75%) wereeither CCr, residual GFR, or Kt/Vurea at start of dialysis
more likely than those referred later to use an AV accessthat are currently reported in the literature are far below
at initiation (39% vs. 10%) and 6 months after startingthe recommended “healthy start” DOQI guidelines.
hemodialysis therapy (74% vs. 56%). Patients referredThe recent DOPPS registry compared renal function
within 1 month of initiating hemodialysis therapy usedat the time of initiation of hemodialysis between Europe
a dialysis catheter for a median of 202 days comparedand the United States from 1998–1999. It showed that
the mean estimated glomerular filtration rates among with 64, 67, and 19 days for patients referred 1–4, 4–12,
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Table 2. Cost analysis with respect to planned or unplanned dialysis in 5 Spanish units
Planned Unplanned
Dialysis sessions of acute patients (1 per patient) 31  $ 254 $ 7,854 172  $ 254 $ 43,688
Other sessions at hospital (overcost or differences
with type I sessions) 47  $ 47 $ 8,789 1023  $ 47 $ 48,081
Hospitalization at dialysis initiation 269 days  $ 169 $ 45,461 3358 days  $ 169 $ 567,502
Hospitalization within the first 6 months 594 days  $ 169 $ 100,386 954 days  $ 169 $ 161,226
$ 162,510 $ 820,497
Difference  $ 657,987
health outcomes between the different dialysis modal-
ities (admittedly, a contentious assumption), economic
evaluation shows that ESRD programs should strongly
encourage continuous ambulatory peritoneal dialysis
(CAPD), or for patients in whom CAPD is not an option,
independent (home or self-care) hemodialysis. It is of
course clear that autonomous dialysis cannot be mas-
tered by many patients currently admitted in renal units.
Consequently, many ESRD programs have low rates of
CAPD utilization and very low rates of independent
hemodialysis, also partly as a result of the financial incen-
Fig. 1. Cost in Euro of the first hospitalization, the first year treatment tives that exist for the nephrologists who care for dialysis
without the first hospitalization, and the total first year of treatment in patients. But as pointed out before, roughly one thirdearly and late referral incident patients admitted in RRT in Ghent
of the patients arrive rather late in the renal unit andduring the year 1998. 1st hospitalization (open box); 1st year (shaded
box); total (black box). are then started on hemodialysis. In fact, assuming that
an average patient starting renal replacement therapy
spends 3.1 years on dialysis before death or renal trans-
plantation, then treating an eligible patient with homeand greater than 12 months before initiating hemodialy-
rather than in-center hemodialysis could result in a costsis therapy, respectively. Compared with LR patients,
saving of more than US$ 135,000 over the 3.1 years. Thethose patients referred at least 4 months before initiating
savings that may result from treating two eligible patientshemodialysis therapy were more likely to use an AV
with home rather than in-center hemodialysis could thenfistula, rather than a synthetic graft, as their first AV
be used to fund fully the treatment of one in-centeraccess (45% vs. 31%). These associations remained after
hemodialysis patient (for 3.1 years). As such, the healthadjustment for age, sex, race, marital status, education,
gains per dollar spent would be maximized. Accordingly,insurance coverage, co-morbid disease status, albumin
ESRD programs should address the barriers that impedelevel, body mass index, and underlying renal diagnosis.
the more widespread use of CAPD and independentThese data show that LR to a nephrologist substantially
hemodialysis; in addition, the financial incentives thatincreases the likelihood of dialysis-catheter use at the
promote in-center hemodialysis should be changed. Oneinitiation of hemodialysis therapy and is associated with
of these barriers is the LR of the patients.prolonged catheter use. Regardless of the time of refer-
Earlier calculations by Campbell et al [5] and Jungersral, only a minority of patients used an AV access at the
et al [8] have revealed that, mainly because of prolongedinitiation of treatment, and greater than 25% had not
initial hospitalization, the LR patient induced an excessused an AV access 6 months after initiation. As recently
of approximately US$19,000 in the early 1980s in thepointed out by us, the differences in vascular access pol-
United States and of FF0.2 million (or approximatelyicy between the United States and Europe may contrib-
US$30,000 per patient) between 1989 and 1991 in France.ute to the greater mortality in US hemodialysis patients
Only a few recent studies have directly calculated the[62].
differences in cost between ERs and LRs in more recent
years.
THE ECONOMIC IMPACT OF Such calculations have been made in five Spanish cen-
TIMELY REFERRAL ters [9] and in the renal unit of the Ghent University
Hospital.According to a recent review of economic evaluation
of the treatment of ESRD [63], and assuming equivalent A total of 362 patients were admitted for RRT in five
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Spanish centers in the years 1996 and 1997 (Table 2). patient care. In case of diabetes, the nephrologist should
assume a more intense responsibility at a serum creati-Planned dialysis refers to a patient admitted in a renal
replacement therapy program with either a peritoneal nine of 2–3 mg/dL.
or vascular access present. The proportion of patients
Reprint requests to Norbert Lameire, M.D., University Hospital, 185
who had visited a nephrology unit, at least 6 months De Pintelaan, 9000 Ghent Belgium.
E-mail: ingrid.verslychen@rug.ac.bebefore the start of dialysis, was significantly greater in
the planned group compared with the unplanned group
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